Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France

Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Desoubeaux, Guillaume, Reichert, Janice M., Sleeman, Matthew, Reckamp, Karen L., Ryffel, Bernhard, Adamczewski, Jörg P., Sweeney, Theresa D., Vanbever, Rita, Diot, Patrice, Owen, Caroline A., Page, Clive, Lerondel, Stéphanie, Le Pape, Alain, Heuze-Vourc'h, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968091/
https://www.ncbi.nlm.nih.gov/pubmed/27266390
http://dx.doi.org/10.1080/19420862.2016.1196521
_version_ 1782445613119438848
author Desoubeaux, Guillaume
Reichert, Janice M.
Sleeman, Matthew
Reckamp, Karen L.
Ryffel, Bernhard
Adamczewski, Jörg P.
Sweeney, Theresa D.
Vanbever, Rita
Diot, Patrice
Owen, Caroline A.
Page, Clive
Lerondel, Stéphanie
Le Pape, Alain
Heuze-Vourc'h, Nathalie
author_facet Desoubeaux, Guillaume
Reichert, Janice M.
Sleeman, Matthew
Reckamp, Karen L.
Ryffel, Bernhard
Adamczewski, Jörg P.
Sweeney, Theresa D.
Vanbever, Rita
Diot, Patrice
Owen, Caroline A.
Page, Clive
Lerondel, Stéphanie
Le Pape, Alain
Heuze-Vourc'h, Nathalie
author_sort Desoubeaux, Guillaume
collection PubMed
description Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence “MAbImprove,” the GDR 3260 “Antibodies and therapeutic targeting,” and the Grant Research program ARD2020 “Biotherapeutics” invited speakers from industry, academic and government organizations to present their recent research results at the Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress held March 31 – April 1, 2016 in Tours, France.
format Online
Article
Text
id pubmed-4968091
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49680912016-08-23 Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France Desoubeaux, Guillaume Reichert, Janice M. Sleeman, Matthew Reckamp, Karen L. Ryffel, Bernhard Adamczewski, Jörg P. Sweeney, Theresa D. Vanbever, Rita Diot, Patrice Owen, Caroline A. Page, Clive Lerondel, Stéphanie Le Pape, Alain Heuze-Vourc'h, Nathalie MAbs Meeting Report Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence “MAbImprove,” the GDR 3260 “Antibodies and therapeutic targeting,” and the Grant Research program ARD2020 “Biotherapeutics” invited speakers from industry, academic and government organizations to present their recent research results at the Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress held March 31 – April 1, 2016 in Tours, France. Taylor & Francis 2016-06-06 /pmc/articles/PMC4968091/ /pubmed/27266390 http://dx.doi.org/10.1080/19420862.2016.1196521 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Meeting Report
Desoubeaux, Guillaume
Reichert, Janice M.
Sleeman, Matthew
Reckamp, Karen L.
Ryffel, Bernhard
Adamczewski, Jörg P.
Sweeney, Theresa D.
Vanbever, Rita
Diot, Patrice
Owen, Caroline A.
Page, Clive
Lerondel, Stéphanie
Le Pape, Alain
Heuze-Vourc'h, Nathalie
Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France
title Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France
title_full Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France
title_fullStr Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France
title_full_unstemmed Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France
title_short Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France
title_sort therapeutic monoclonal antibodies for respiratory diseases: current challenges and perspectives, march 31 – april 1, 2016, tours, france
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968091/
https://www.ncbi.nlm.nih.gov/pubmed/27266390
http://dx.doi.org/10.1080/19420862.2016.1196521
work_keys_str_mv AT desoubeauxguillaume therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT reichertjanicem therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT sleemanmatthew therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT reckampkarenl therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT ryffelbernhard therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT adamczewskijorgp therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT sweeneytheresad therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT vanbeverrita therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT diotpatrice therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT owencarolinea therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT pageclive therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT lerondelstephanie therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT lepapealain therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance
AT heuzevourchnathalie therapeuticmonoclonalantibodiesforrespiratorydiseasescurrentchallengesandperspectivesmarch31april12016toursfrance

Ejemplares similares